Robust research findings must demonstrate both internal stability (consistent under perturbation) and external validity (replicable in independent data). This document describes validation approaches for the pathway framework.
In high-dimensional biological data:
- Many analytical choices are arbitrary
- Small changes can produce different results
- Overfitting to specific cohorts is common
- Publication bias favors novel findings
Stability testing and replication protect against false discoveries and overinterpretation.
Procedure:
- Resample individuals with replacement (B times, typically B=1000)
- Recompute pathway scores and clustering for each bootstrap
- Assess consistency of:
- Pathway rankings
- Subtype assignments
- Key associations
Metrics:
- Bootstrap confidence intervals for pathway scores (95% CI)
- Cluster stability: proportion of times pairs co-cluster (threshold: ≥0.80 for stable clusters)
- Rank correlation of pathway importance across bootstraps (Spearman ρ ≥ 0.70 indicates stability)
Procedure:
- Randomly hold out X% of samples (e.g., 20%)
- Refit models on remaining 80%
- Repeat K times
- Measure consistency across subsamples
Useful for:
- Detecting results driven by small subsets
- Identifying influential observations
- Estimating effective sample size
Procedure:
- Vary key parameters within reasonable ranges:
- Variant weighting schemes
- Network propagation α
- Number of clusters K
- Assess stability of main conclusions
Stable results: Key findings should persist when parameters vary by ±20% from defaults. Specifically:
- Variant weighting: α ± 0.2 should not change top-10 pathway rankings
- Network propagation: α ± 0.1 should maintain >80% overlap in enriched genes
- Cluster number K: results should be interpretable for K ± 1
For methods with random initialization (clustering, VAE):
- Run multiple times with different seeds
- Compare solutions across runs
- Report only findings consistent across initializations
Replication is assessed at the pathway and subtype level, not by exact gene overlap.
| Level | Expectation |
|---|---|
| Individual variants | Will differ |
| Specific genes | May differ |
| Pathway enrichments | Should be directionally consistent (Spearman ρ ≥ 0.60) |
| Subtype structure | Should show similar patterns (ARI ≥ 0.50, Jaccard ≥ 0.40) |
- Train: Develop model on discovery cohort
- Freeze: Fix all parameters and thresholds
- Apply: Run frozen pipeline on replication cohort
- Compare: Assess consistency of findings
Pathway-level:
- Rank correlation of pathway disruption scores (Spearman ρ ≥ 0.60 for strong replication)
- Overlap of top-K pathways (Jaccard index ≥ 0.50 for top-20 pathways)
- Directional consistency: ≥75% of significantly disrupted pathways show same direction of effect
Subtype-level:
- Similar number of clusters (±1 cluster tolerance)
- Relative size consistency: largest cluster size differs by <15% between cohorts
- Consistent pathway signatures per subtype (cosine similarity ≥ 0.70)
- Comparable phenotype associations (if available): correlation r ≥ 0.50
Full replication is rare. Consider:
- Directional consistency: Same direction of effect (≥70% agreement on top pathways)
- Biological coherence: Same biological themes even if specific pathways differ (semantic similarity ≥ 0.60 using GO hierarchy)
- Effect size attenuation: Smaller effects in replication (expected 20-40% attenuation due to winner's curse)
Procedure:
- Randomly permute case/control labels (or outcome variables)
- Rerun full analysis
- Results should be null (no significant pathways)
Detects: Confounding, data leakage, analysis bugs
Procedure:
- Replace pathway definitions with random gene sets of same size
- Rerun pathway scoring
- Real pathways should outperform random sets
Detects: Spurious aggregation effects, pathway size artifacts
Procedure:
- Build model using only batch/technical variables
- Should not predict biological outcomes
Detects: Batch effects masquerading as biology
Procedure:
- Exclude one chromosome from training
- Test if predictions generalize
Detects: Overfitting to specific genomic regions
| Element | Description |
|---|---|
| Bootstrap CIs | 95% confidence intervals from resampling |
| Stability metrics | Cluster stability, rank correlation |
| Effect sizes | Not just p-values |
| Sample sizes | Per group, after QC |
| Element | Description |
|---|---|
| Cohort description | Demographics, ascertainment, sequencing |
| Frozen parameters | All settings fixed from discovery |
| Comparison metrics | Quantitative replication assessment |
| Discrepancies | Honest reporting of differences |
| Control | Outcome |
|---|---|
| Permutation test | P-value from null distribution |
| Random gene sets | Comparison to real pathways |
| Batch prediction | Should be non-predictive |
Problem: Using the same data for discovery and validation
Solution: Strict separation of training/test sets; pre-registration of hypotheses
Problem: Testing many comparisons, reporting only significant ones
Solution: Correct for multiple testing; report all tests performed
Problem: Hypothesizing After Results are Known
Solution: Distinguish exploratory vs. confirmatory analyses; pre-register when possible
Problem: Only reporting successful replications
Solution: Publish failures; use registered reports
Problem: Complex models that don't generalize
Solution: Regularization; cross-validation; simpler models
- Bootstrap confidence intervals computed
- Cluster stability assessed (if clustering used)
- Parameter sensitivity tested
- At least one negative control performed
- Cross-cohort replication attempted (or acknowledged as limitation)
- All analytical choices documented
- Effect sizes reported (not just p-values)
- Multiple testing correction applied
- Limitations explicitly stated
| Metric | Threshold | Interpretation |
|---|---|---|
| Cluster stability (co-clustering) | ≥ 0.80 | Pair of samples clusters together ≥80% of bootstraps |
| Rank correlation (pathways) | Spearman ρ ≥ 0.70 | Stable pathway importance across bootstraps |
| Cross-cohort pathway correlation | Spearman ρ ≥ 0.60 | Strong replication of pathway scores |
| Top-K pathway Jaccard | ≥ 0.50 | At least half of top-20 pathways overlap |
| Directional consistency | ≥ 75% | Same enrichment direction in replication |
| Adjusted Rand Index (ARI) | ≥ 0.50 | Moderate cluster agreement across cohorts |
| Subtype Jaccard overlap | ≥ 0.40 | Acceptable sample assignment agreement |
| Pathway signature similarity | Cosine ≥ 0.70 | Similar subtype pathway profiles |
| Phenotype correlation | r ≥ 0.50 | Comparable clinical associations |
| Effect size attenuation | 20-40% | Expected reduction in replication cohort |
| Parameter sensitivity | ±20% | Results stable within this range |
| Validation Type | Purpose | Key Methods |
|---|---|---|
| Bootstrap | Uncertainty quantification | Resampling with replacement |
| Stability | Robustness to perturbation | Subsampling, parameter variation |
| Negative controls | Detect artifacts | Permutation, random gene sets |
| Replication | External validity | Independent cohorts |
- Limitations - Known constraints of the framework
- Synthetic Example - Worked example with validation